SCHEMBL5232198

SCHEMBL5232198

CCOC(=O)c1cn(-c2ccc(C=Cc3ccccc3)cc2)nc1N(C(=O)C1CCC(C)CC1)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
ALDH1A1 P00352 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
GLA P06280 2/20 0.42
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
CA12 O43570 4/20 0.41
CA9 Q16790 4/20 0.41
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
POLB P06746 1/20 0.36
DRD4 P21917 1/20 0.36
USP2 O75604 1/20 0.35
ATM Q13315 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14459836 1.00 NPC1 (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL5230314 1.00 NPC1 (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL5230442 0.93 NPSR1 (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL5230434 0.93 NPSR1 (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL14459841 0.93 NPSR1 (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL5318141 0.92 NPSR1 (0.47) NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL5318137 0.92 NPSR1 (0.47) NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL14459844 0.92 NPSR1 (0.37) NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL5233131 0.92 NPSR1 (0.37) NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1
SCHEMBL5233124 0.92 NPSR1 (0.37) NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730116-B1 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORP (US) 2007-09-05 EP disclosed
US-20070167507-A1 4-Carbox pyrazole derivatives useful as anti-viral agents GLAXO GROUP LIMITED (GB) 2007-07-19 US disclosed
EP-1730116-A1 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-13 EP disclosed
WO-2005092863-A1 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167507-A1 4-Carbox pyrazole derivatives useful as anti-viral agents HAVCR2, RPL35, ZC3HAV1L NPC1 352/4885RAB9A 1879/4885SMN1; SMN2 3430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.